Jun 26, 2023 7:00 am EDT Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
May 22, 2023 7:00 am EDT Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board
May 10, 2023 7:00 am EDT Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference
May 4, 2023 4:01 pm EDT Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates
Feb 2, 2023 9:54 pm EST Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants
Feb 2, 2023 4:01 pm EST Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants
